You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
McKinsey
Harvard Business School
Colorcon

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 5,210,370

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,210,370
Title: Lightweight weapon stabilizing system
Abstract:A gun system comprising a recoiling cannon assembly, a stationary carriage having a cradle, and a campath and cam follower mechanism for moveably mounting the cannon assembly on the cradle for travel along a two-stage curvilinear recoil path. The first stage has a linear portion shaped to maintain prefiring orientation, and a curved portion with a decreasing radius of curvature in the direction of travel (i.e., recoil) to accelerate the cannon assembly upwards. The second stage, which may be straight or have a curved configuration different from that of the first stage, causes the cannon assembly\'s upward motion to be decelerated in a controlled manner. A recoil buffer assembly has deceleration characteristics matched in a predetermined relationship to the configuration of the curvilinear path, so that the instantaneous stabilizing moment of the reaction to the upward force of the recoiling cannon assembly and the moment of the static weight of the gun system. The campath mechanism can be mounted on the cannon assembly or on the cradle, with the cam follower mechanism correspondingly mounted on the cradle or cannon mechanism respectively.
Inventor(s): Mraz; William A. (Middlebury, VT), Buttolph; Martin E. (Newport, VT), Farney; Michael J. (Newport Center, VT)
Assignee: Royal Ordnance (London, GB2)
Application Number:07/608,299
Patent Claims:see list of patent claims

Details for Patent 5,210,370

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Royal Ordnance (London, GB2) 2010-05-11 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Royal Ordnance (London, GB2) 2010-05-11 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Royal Ordnance (London, GB2) 2010-05-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Dow
Baxter
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.